

Application handbook

March 2026 grant round



The 2026 grant round is open for submissions from Thursday 5 March until we reach the **500 application cap** or Thursday 2 April, whichever is first.



Please note that application handbooks are revised regularly, so please ensure you are using the correct version.

Table of Contents

1	What type of research do we fund?.....	2
2	Who can apply for a grant?	4
3	When can you apply?	7
4	What funding can you apply for?	8
5	How are applications assessed?	13
6	Questions? Contacting Worldwide Cancer Research	15
7	Appendix 1: Grant Terms & Conditions	16

1 What type of research do we fund?

1.1 Our goal is to support research that seeks to answer the difficult questions in cancer biology. What we are looking for in an application:

Starting new ideas

We are looking for innovative research that takes intellectual risks. To us, that means helping researchers turn their bold idea into reality. And if there's a risk of failure, we are willing to take it, if the rewards for success are worth it.

We want to see ideas which have the potential to start new lines of research and to tell us something new about cancer and how it could be prevented, diagnosed or treated.

We want to make the most of our supporters' generous donations by funding standalone research projects. Projects should seek to answer a focused research question, not be an incremental piece of research tied to a larger programme grant.

Exciting and creative

We are looking for ideas that excite us. The ones that make us go, "I wish I had thought of that". We are looking for proposals with a creative approach to answering fundamental questions that could change how we think about cancer. Often these are ideas that other funders may overlook.

Scientific quality

We want to see the most exciting and creative new ideas, but we are also responsible stewards of our supporters' donations. We need to see robust scientific reasoning and appropriate solid methodology to back it up. The aims of a project should be feasible with the time and resources requested, and with the expertise of the research team.

Transformative impact

We support blue-sky thinking in research and want to direct funding towards projects that could transform an area of cancer research or one day have a major impact on the lives of people with cancer. While impact on cancer patients is a priority for us and our supporters, we recognise that important discoveries take time to bear fruit and that it may be many years before the research leads to lives saved or improved.

1.2 We award grants to support fundamental or translational research into the prevention, diagnosis or treatment of cancer. We do not prioritise any field of research; we welcome research projects with a strong scientific hypothesis that draws on epidemiological, behavioural and clinical data to provide a starting point for a new avenue of research. Multidisciplinary or discipline-hopping projects are encouraged where this helps stimulate innovation.

1.3 We do not support clinical research, including clinical trials, patient care, nursing or healthcare delivery research. Neither do we support other types of applied cancer research, such as policy, public health or psychosocial research. This list is not exhaustive.

Proposals that contain a small clinical element as an essential part of a basic or translational research project are often permitted, but you are advised to contact grants@worldwidecancerresearch.org for advice before submitting your proposal.

1.4 We will consider applications in which human samples or data are used as an essential part of a basic/translational research project if the following conditions are satisfied:

- Clinical costs cannot be requested in the budget or charged to a Worldwide Cancer Research grant. This includes costs of patient or volunteer recruitment, patient expenses, the salaries of purely clinical staff, such as research nurses, honorariums or consultancy fees for clinical collaborators. It is also not acceptable to include costs for the clinical investigation, diagnosis or follow-up of patients involved in the research study.
- Projects that rely upon a large number of human samples or extensive clinical data must have this resource available through existing biobanks, databases or cohorts. Projects will not be accepted that would involve a considerable effort to recruit patients or volunteers for samples or data; Worldwide Cancer Research funded projects must focus on conducting hypothesis-led research and not on infrastructure development. This applies equally to all types of research, including epidemiological studies.

1.5 Applications on cancer symptoms or treatment side effects are accepted only if there is a very clear link to improving cancer survival. Studies investigating the biology of a side effect or symptom alone are unlikely to be accepted.

1.6 Basic studies into fundamental cellular processes, mechanisms and molecules are within remit if the research aims to improve the understanding of cancer biology. If a project is to study the normal functioning of cellular processes, mechanisms or molecules - or to study very basic models such as yeast - evidence supporting the relevance to cancer biology must be laid out.

1.7 We need to work together to advance research quickly and support the best ideas, so we are partnering with several other cancer research funders for this grant round. This will enable more cutting-edge ideas with the potential for impact to be explored. These additional opportunities for funding are available depending on the cancer type the project focuses on or the country in which the applicant resides. For the 2026 grant round, you can find our partners here: <https://www.worldwidecancerresearch.org/who-we-are/co-funding-opportunities/>

1.8 We still welcome grant applications for projects on any cancer type and from any country. By working with our research partners, we are able not only to fund a greater number of high-quality research identified through the review process, but also extend our reach to more applicants in more parts of the world. No additional action is needed by an applicant for a project that may be eligible for co-funding. Any successful applicants eligible for co-funding will be contacted by our Research Funding Team. More information on our partnerships can be found on our website.

1.9 Our Use of Animals in Research policy states that we are committed to ensuring the animal research we fund is as robust and reproducible as possible and that the highest standards of laboratory animal welfare are met. For further details, see our Use of Animals in Research policy (<https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/>). **If you wish to apply with an animal research project and have further questions, please get in touch with us at grants@worldwidecancerresearch.org before you submit your proposal.**

1.10 Worldwide Cancer Research grants are awarded for novel research proposals that are entirely the original work of the applicants. Any use of another investigator's work or ideas must be fully attributed to the original source. The charity reserves the right to investigate if plagiarism is suspected; this may involve the disclosure of information to third parties and the use of plagiarism-checking software. If evidence of plagiarism is found, in the opinion of Worldwide Cancer Research, the application will be immediately rejected, and the applicants may be barred from applying in future. The charity also reserves the right to inform the principal investigator (PI)'s institution. The PI takes full responsibility for the originality of the project proposal, and the submission of an application constitutes acceptance of these terms by all applicants.

If you have any questions about the points above, or are in any doubt about whether your proposal will be considered within remit, please contact us at grants@worldwidecancerresearch.org before you submit an application.

2 Who can apply for a grant?

2.1 Our project grants are awarded to the Host Institution. The Host Institution is responsible for ensuring all requirements of our grant terms and conditions and policies are complied with by the Principal Investigator (PI) and others involved with the delivery of the research.

2.2 The PI is the person with the main responsibility for writing the application and designing and directing the research project. The PI is also responsible for ensuring all requirements in this handbook are complied with and must follow our grant terms and conditions in execution of the award supported by the Host Institution.

2.3 The PI must be employed at a recognised, non-profit research institution. Honorary contracts and emeritus positions are usually acceptable. Researchers at commercial, for-profit organisations, e.g. biotechnology and pharmaceutical companies, cannot apply for a grant. It is also not permitted for a research institution to transfer Worldwide Cancer Research grant funds to a commercial organisation except for payment for specific services, items and reagents used in the project. This includes transferring money to spin-out companies from the laboratory or institute.

2.4 Individual scientists from commercial organisations can be named as collaborators if they provide specific expertise or reagents to the project. The nature of their involvement must be made clear. Scientists from commercial organisations cannot be co-applicants.

2.5 The PI is usually a PhD-qualified, tenured or tenure-track research group leader with at least three years of post-doctoral research experience. Other suitably qualified persons, e.g., medical doctors, with appropriate research experience may also apply as the PI. Post-doctoral researchers with more than three years of postdoctoral research experience **at the time of applying** are also eligible to apply for a grant as a PI or as a co-applicant.

2.6 Applicants at a post-doctoral level (with more than three years postdoctoral experience) or an equivalent level are eligible to apply as PI when they are not yet independent investigators, however they must name their group head as co-applicant on the grant. PIs who have established their first research group within the past two years are advised to add their head of department as a co-applicant. All co-applicants, group heads or heads of departments are expected to have a minimum contribution of 5%, which could be as a mentor.

2.7 You cannot apply to Worldwide Cancer Research for a project grant (either as a PI or co-applicant) if you are currently applying for, or have received, funding from the tobacco industry or bodies substantially funded by the tobacco industry, within the last 10 years. For further information see our policy section at <https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/>.

2.8 PIs working in groups or at institutes that receive long-term, or core research funding may apply for a grant, but only for a research project that is clearly distinct from that supported by the other funding. Before a grant is awarded, we will request documents relating to the other funding to confirm there is no overlap with our award.

2.9 The Host Institution must be able to accept the terms and conditions within our grant contract, which can be found in Appendix 1 of this handbook. The grant contract is not negotiable except in the rare situation that a clause conflicts with local or national law. Applying to Worldwide Cancer Research is taken as an agreement to the terms of our grant contract. Therefore, PIs must ensure the relevant grant or finance officer at their institution has reviewed the contract in detail before an application is submitted. If an institution is unable to agree to the terms of the grant contract when an offer is made, the offer will be withdrawn.

2.10 The PI must have a contract of employment that will last for at least the duration of the grant requested or be able to show evidence that their current contract would be extended if the grant were awarded.

2.11 A research group can only submit one application per grant round. For example, if you are the PI on an application, no member of your research group can be a PI on a second application in the same round. You or another member of the same research group can be a co-applicant or collaborator on other applications in the same grant round. If, at any stage of a grant round, multiple PIs are found to be from the same research group, all the applications will be rejected immediately, and the group may be barred from applying in the future.

2.12 If the PI on an application is rejected at the preliminary triage review stage of a grant round, they can submit applications in subsequent grant rounds, so long as the research proposal is sufficiently different (at least 50%) from the research proposal that was rejected at preliminary triage review. To be considered significantly different, the aims or the methodology proposed to address the research proposal must have evolved or altered noticeably, this cannot be a change in model (e.g. cell line or cancer type) using the original methods. The application should present novel approaches or new milestones to be treated as a '**new**' application.

2.13 If you wish to re-submit a project (or one very similar) that has been rejected in a previous grant round, but had passed preliminary triage review, you can re-apply as a '**resubmission**'. **A project can only be resubmitted once**. You will be asked to address any previously provided feedback. Note that resubmissions are considered in equal competition with all other applications in the round and are not guaranteed to pass preliminary triage.

2.14 If the Scientific Advisory Committee formally invites a grant to be resubmitted in a revised form, you may submit it in the next grant round. These are called '**invited resubmissions**'. Invited resubmissions are guaranteed to pass preliminary triage and will go out to external peer review. Invited resubmissions will be discussed at the Scientific Advisory Committee meeting. Projects are only re-invited once, and the PI cannot re-submit the same project to Worldwide Cancer Research after that.

2.15 If the PI submitted an application in a previous grant round and it was not funded, they can submit a '**new**' application that must be sufficiently different to previously submitted applications.

2.16 If the PI on an application is successful in a grant round, they cannot apply in the next grant round as a PI but can apply in the following grant rounds. They can, however, apply in the next grant round as a co-applicant. Please note that successful co-applicants can apply in the next grant round either as PI or co-applicants.

2.17 Other researchers who would be substantially involved in managing the project can be included as co-applicants. **Co-applicants can be at post-doctoral level or above so long as they are to be substantially involved in managing the project.** Co-applicants do not need to be at the same institution as the PI.

2.18 Where a project is collaborative and involves more than one investigator and/or research institution, one of the applicants must take the role of PI. This must be the investigator whose research group will carry out most of the work on the project.

2.19 If an award is made for a collaborative project, the PI's institution, will become the Host Institution for the award and be legally responsible for the delivery of the project as outlined in the application. It is the Host Institution's responsibility to put in place an arrangement to reimburse costs incurred by other institutions during the project as outlined in the terms and conditions. **Worldwide Cancer Research takes no responsibility for ensuring the costs of collaborating laboratories are reimbursed.**

2.20 You may apply to other organisations at the same time as Worldwide Cancer Research for funding to support the same project. However, we must be informed of any such 'parallel' applications in the relevant section of the application form.

2.21 If you choose to submit parallel applications to fund the same project and are offered a grant by both Worldwide Cancer Research and another organisation, you will be asked to choose which grant to accept. You are not permitted to double-fund a project or use your Worldwide Cancer Research grant for a different programme of work than that described in the grant application.

2.22 In rare cases, where a parallel award is much smaller than the Worldwide Cancer Research grant, a PI may be permitted to keep both grants at the discretion of Worldwide Cancer Research, with an appropriate reduction in budget to remove any overlap in funding.

3 When can you apply?

3.1 Once registered on our grant system, you can begin preparing an application when a grant round opens. The 2026 grant round will open on Monday 23rd February 2026. Please note that we are currently in the process of migrating to a new grant management system. We aim to have this platform online for mid-February. All users will be required to register on the new platform even if they had an account with our old system. Further updates will be provided on our website. Completed applications can only be submitted during the submission period, Thursday 5th March until the **500-application cap is reached** or Thursday 2nd April 2026, whichever is first. Please note that unsubmitted or deleted applications will be permanently deleted from our system after 60 days of the submission closing date.

- 3.2 Worldwide Cancer Research will only accept the first 500 applications submitted in the grant round. Once this cap is reached no further applications can be submitted and the grant round will be closed early. **An application is only considered submitted once it has been approved on the grant system by both the Head of Department and Authorising Officer.**
- 3.3 You are advised to allow plenty of time to submit your grant application. **It must be approved by your Head of Department and Authorising Officer before the cap is reached or before the grant deadline.** We will not extend the deadline to allow these approvals to be completed, or because of any confusion about how the online grants system works. Grant deadlines will only be extended if we accept fault for causing an unreasonable delay to your submission, e.g., because of a verified technical failure in the online grants system.
- 3.4 **For the 2026 grant round, the submission period will close when the cap of 500 is reached. Otherwise, applications must be submitted by 17:00hrs (British Local Time) on Thursday 2nd April 2026. Please note that in the 2025 funding round the 500-application limit was reached before the closing date and we expect the same to occur in 2026**
- 3.5 We cannot guarantee to respond before the grant deadline to any queries sent less than 48 hours before the deadline, although we will try to do so. Please remember that we are based in the UK.
- 3.6 Successful applications submitted to the March 2026 grant round will be offered a grant starting from 1 January 2027. We may allow the start date to be deferred by up to 6 months, providing our prior approval has been sought.

4 **What funding can you apply for?**

- 4.1 Worldwide Cancer Research offers grants for 1-3 year research projects. Grants cover the direct costs of the project, including research consumables, the salaries of research staff working directly on the project, travel to conferences or to visit collaborators, and any essential services or small pieces of specialist or unusual equipment. For a more detailed description of eligible budget items, please see Table 1. Please note that we will not increase the budget after the application stage, so please take inflation into account.
- 4.2 The Host Institution must cover all indirect and overhead costs. This is not negotiable even if it is standard practice for your institution to charge overheads to external grants.
- 4.3 **The maximum budget permitted is £275,000**, but it should be noted that most of our 3-year grants have a budget of between £200,000 and £250,000.

- 4.4** You must submit a research proposal that describes a discrete project achievable within the duration of the grant and with the financial support requested. Applications which describe a large programme of work – for example, the work of an entire laboratory – and then request a contribution towards it, will be rejected. The grant budget must reflect the work described in the research proposal.
- 4.5** We will not accept applications where it appears that the main purpose of applying for funding is the purchase of equipment or the development of research infrastructure such as tissue banks, patient cohorts or databases. Some specialist equipment or infrastructure development can be included in a Worldwide Cancer Research grant, but only as a small, essential part of a hypothesis-led research project. Projects that concern research in which the main body of work is computational can request data storage and computing power or computing time costs when well-motivated and justified.
- 4.6** PhD student salaries/stipends can be included in a project grant budget. Note that project grant applications which include a PhD student will be assessed only on the scientific strength of the project, not on the educational benefits for the student.

Table 1: Constructing your budget – what can you charge to a Worldwide Cancer Research grant?

Staff Salaries	
Permitted	Not Permitted
<ul style="list-style-type: none"> ○ One (occasionally two) research staff who will be employed specifically and fully dedicated to work on the project. ○ This can be any type of research staff, e.g., post-doc, PhD student, technician, graduate research assistant, clinician scientist, etc. The salary justification MUST detail why a staff member with a specific level of experience is requested, referencing the experimental plan and the skill level needed. If a person is named, please explain why they were chosen. <p><i>Note that it is rare for our scientific committee to approve 2 salaries on a project grant. If requesting 2 posts, you are advised to justify the second post very carefully.</i></p> <ul style="list-style-type: none"> ○ Degree fees can be requested along with stipend support for PhD Students (the total amount should be entered in the Gross Salary section and breakdown details given in the justification). ○ Please account for any annual increases for inflation or projected pay awards in the requested salaries and note that the grant commences in the next calendar year. ○ If you intend to have a full-time researcher 100% committed to the project whose salary is covered by another funding source, but would like to request research consumables, you must name the researcher in this section. Please put £0 as the requested salary, explain why the researcher is ideal for the project, and provide details of the funding source. The funding source must only be contributing salary (e.g. PhD scholarship). ○ The PI's salary can be requested only if the PI is a post-doctoral researcher with 3-10 years post-doctoral experience who is trying to establish independence. A mentor (either the Head of Department or a Research Group Head) must be named as a co-applicant in this case. 	<ul style="list-style-type: none"> ○ No more than 2 full-time salaries can be requested. ○ You cannot request the salary or partial salary for anybody who has a tenured, tenure-track or open-ended post, or whose salary is guaranteed and funded by the institution in another way. ○ We do not under any circumstances offset the salaries of people employed by the institution as core support staff (e.g., technicians). If fees have to be paid for core services provided within the institution (e.g., statistics, bioinformatics, sequencing services) then include these fees under 'Other', not in the salary section. ○ The salary of the PI cannot usually be requested. The only exception to this rule is detailed on the left. ○ Purely clinical staff, e.g., research nurses involved in patient recruitment, cannot be included in the salary budget. ○ We do not cover the cost of recruiting staff members.

Research Consumables	
Permitted	Not Permitted
<ul style="list-style-type: none"> Our total standard consumables allowance is £15,000 per year for each researcher working full-time (100% committed) on the project. This covers routine research consumables e.g., glassware, plasticware, tissue culture, molecular biology, and immunohistochemistry. If you are requesting the salary of a researcher who is not working full-time (100% committed) on the project, you are entitled to request the commitment % of the £15,000 per year consumables allowance. For example, if you are requesting the salary for a researcher working 60% on the project, you are entitled to claim £9,000 per year ($15,000 \times 0.6$). You can request consumables for a full-time researcher whose salary is covered solely by another funding source only if they are 100% committed to the project. Please see the Staff Salaries section for details. You must break down your consumables' request under at least 3 general headings (using the "Add Consumable" button), for example 'tissue culture', 'PCR', 'immunohistochemistry'. In exceptional cases, the standard allowance can be increased to £30,000 a year if the project requires two full-time members of staff. 	<ul style="list-style-type: none"> Do not include unusual, high-cost or non-consumable items in the consumables section – these should be listed in the budget section headed 'Other'. Consumables for research positions not listed in the salaries section cannot be claimed. Research consumables totalling over £30,000 per year.
Animals	
Permitted	Not Permitted
<ul style="list-style-type: none"> Costs for the purchase, importation, housing and maintenance of animals can be included in your budget. There is no maximum animal budget. All animal costs must be justified. Animal costs higher than £10,000 per year must be well justified. 	<ul style="list-style-type: none"> Animal research licences/certification and training courses are not eligible costs.
Equipment	
Permitted	Not Permitted
<ul style="list-style-type: none"> Funds can be requested for small pieces of specialist or unusual equipment that are essential for the project. Small pieces of routine equipment can be included only if the PI is a new group leader within the first three years of setting up their first laboratory. 	<ul style="list-style-type: none"> Standard office computers (with one exception, see left) and tablets cannot be included on the grant. Standard equipment that ought to be available in most research institutions e.g., pipettes, refrigerated centrifuges, PCR machines, gel apparatus (with one exception, see left) are not admissible.

<ul style="list-style-type: none"> ○ If the PI is based at an institute in a low- or middle-income country (https://www.oecd.org/dac/financing-sustainable-development/development-finance-standards/daclist.htm), they can request routine equipment regardless of their seniority level provided the main purpose of the grant is not solely the purchase of new equipment. ○ One laptop/computer per full-time researcher who will be 100% committed to the project may be requested. This is allowed only if it is essential to the project (e.g., required for data processing) and not standard computer work (e.g. data analysis, writing papers etc.). ○ Equipment should usually be purchased at the start of the project. 	<ul style="list-style-type: none"> ○ We do not offer equipment grants. Do not request large, expensive or numerous items of equipment that take up a significant proportion of the grant budget. Your application will be rejected.
---	--

Travel

Permitted	Not Permitted
<ul style="list-style-type: none"> ○ Funds for conference registration/travel can be requested. The standard allowance is £500 per year, for each full-time researcher whose salary is paid by the grant. ○ Funds for other travel can also be requested, e.g., visits to collaborating laboratories or travel for patient and public involvement, but these must be itemised separately to conference travel and well justified. 	<ul style="list-style-type: none"> ○ No conference registration/travel funding can be requested for any staff whose salaries are not paid by the grant, including the PI and co-applicants.

Other

Permitted	Not permitted
<p>These costs usually fall into the following categories:</p> <ul style="list-style-type: none"> ○ High-cost items or experiments, e.g., microarrays or SILAC. ○ Fees for external or internal services, such as antibody production, DNA sequencing or statistics support. ○ Specialised software specific to the proposed research is permissible. This should not include standard software licenses (e.g. Microsoft Office, GraphPad). ○ Data storage and/or computing time costs may be included in the application. This is only allowable for projects that anticipate generating a lot of data. This must be well justified, and a data management plan may be requested. Please also provide an estimate of the amount of storage space required. 	<p>Do not include:</p> <ul style="list-style-type: none"> ○ Publication costs. We have a separate fund to support the costs of open access publishing – https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/ ○ Institutional overheads and indirect costs, including equipment maintenance, journal subscriptions, secretarial support, advertising, recruitment, postdoctoral training, office stationery, etc. ○ Clinical costs. This includes the costs of patient/volunteer recruitment, the investigation, diagnosis, treatment or follow-up of patients providing samples for a research study, and honorarium or consultancy payments to clinical collaborators.

5 How are applications assessed?

- 5.1 After the grant deadline, all applications are checked by the Research Funding team to ensure they have been completed correctly and that all the required information has been supplied. Applications requiring minor changes may be returned for amendment, but those with major omissions or errors will be rejected without further review.
- 5.2 If your application is returned for administrative changes, it has not yet been checked for compliance with our research funding strategy and policies. The return of your application for changes does not imply that your application has been judged to be within our funding remit and accepted for scientific review.
- 5.3 Applications are reviewed by senior members of the Research department to ensure they comply with our funding strategy and policies. Any applications which do not comply will be rejected without further review. **Please note the Worldwide Cancer Research funding remit is always interpreted conservatively.**
- 5.4 The first round of scientific review is a preliminary triage by our Scientific Advisory Committee (SAC). Each application is allocated to the two committee members most suitable to review it, and they judge whether it meets our research strategy criteria (see Section 1) and is likely to be competitive for funding. If both SAC members agree an application does not meet the criteria or is not competitive, then it is rejected (triaged) without further review.
- 5.5 When preliminary triage is complete, applicants rejected at this stage will be notified by email. There will be **no feedback** available for applications rejected at preliminary triage and the committee's decision is final.
- 5.6 The current membership of the Scientific Advisory Committee can be found on our website (<https://www.worldwidecancerresearch.org/who-we-are/our-scientific-advisory-committee/>).
- 5.7 Applications which are kept in the round after preliminary triage are then sent to expert peer review. We aim to secure at least three reviews for each application.
- 5.8 Worldwide Cancer Research is currently transitioning to a peer review college model of expert peer review. This will start in the 2026 grant round.
- 5.9 External reviewers are asked to assess applications on the following criteria:
 - **Relevance** – Is the proposed research relevant to cancer? If successful, will the results contribute significantly to our understanding of cancer or fundamental biology relevant to cancer, or to the translation of such research into clinical benefit?

- **Originality** – Is the proposed research addressing new and interesting questions that we currently do not have answers to? Are the results of other groups working in this area likely to make this proposal redundant?
- **Experimental design** – Is the proposed research project and the experiments described in the application designed appropriately to answer the questions being addressed?
- **Team expertise** – Do the applicant(s), as reflected in their CV(s) and additional information provided, give confidence that they will be able to carry out the proposed research project successfully?
- **Achievability** – Is the proposed research project achievable with the resources requested in the application and the other resources that the applicant(s) have indicated will be available?

5.10 All applications that include proposals to use mammals with special protection under UK law (cats, horses, dogs and non-human primates) will undergo an additional layer of peer review by the UK's National Centre for the 3Rs (<https://www.nc3rs.org.uk/>) for an expert assessment of animal welfare. Our full Use of Animals in Research policy is available at <https://www.worldwidecancerresearch.org/for-researchers/our-research-policies/>

5.11 Applicants may use generative AI tools for their applications but will need to acknowledge their use. We also expect applicants to use AI tools responsibly in accordance with relevant legal and ethical standards. Peer reviewers are asked not to use generative AI to review the applications. If we suspect the review has been AI generated this review will not be used to assess the application and the reviewer may be barred from applying for funding from Worldwide Cancer Research.

5.12 All applications that are externally peer reviewed are assessed by the Scientific Advisory Committee. They will conduct a secondary triage to further remove any applications that have no prospect of being funded. The remaining applications will be discussed, scored and ranked at the Scientific Advisory Committee meeting. Alignment with our research strategy will also be considered.

5.13 Applications are awarded funding based on the ranked list until the allocated funds are spent. The recommendations of the Scientific Advisory Committee will be presented to the Board of Trustees who will make the ultimate decision on funding based on these recommendations and overall affordability. Whilst we will always strive to fund as much high-quality research as possible, some projects with good reviews will not be funded due to limited funds.

5.14 Successful applicants will be notified by email as soon as possible after the Board of Trustees has ratified the recommendations from the Scientific Advisory meeting and asked to confirm informally, if they will be accepting the grant. The grant award agreement will follow soon after; the grant cannot be activated until we have received a signed copy of the agreement.

5.15 Unsuccessful applicants will usually be notified within one month of the Board of Trustees meeting.

5.16 Where expert reviewers have provided comments to be fed back to the applicant, we aim to provide these (to both successful and unsuccessful applicants). Please note that the referees' views may vary markedly from each other, and funding decisions are not made solely on external reviews. We will not enter a debate regarding the content of these reports.

6 Questions? Contacting Worldwide Cancer Research

Please send all queries to the Research Funding team email address:
grants@worldwidecancerresearch.org

If you wish to speak with someone urgently, our main office number is +44 (0)300 777 7910.

For the avoidance of doubt:

We will not extend the deadline to allow the final approvals to be made, or because of any confusion about how the online submission process works. It is your responsibility to ensure that your grant application is completed with enough time remaining to contact the Research Funding team (grants@worldwidecancerresearch.org) if you have any difficulties with the submission process. Please remember that we are based in the UK. We cannot guarantee to respond before the submission deadline or when the 500 application cap is reached to any queries sent in the final 48 hours of the submission window, although we will try to do so.

Grant deadlines will only be extended if we accept that Worldwide Cancer Research was at fault for unreasonably delaying the submission of your grant. Technical failures of the grants system will only be accepted as a reason to extend the deadline if they are verified by the IT Company that hosts the system.

7 Appendix 1: Grant Terms & Conditions

In 2024 Worldwide Cancer Research undertook a review of their Award Terms and Conditions which had remained largely unchanged for over 10 years. Most of the content remains the same but, to help ensure they are not a blocker to potential applicants and enable the Charity to fund ideas from anywhere, there are four key areas that have been updated:

- Legal contract will now only be between the Charity and the Host Institution to remove any concerns of personal liability to the Principal investigator. The Principal Investigator will still be required to acknowledge that they have 'read and understood' all conditions under which the grant has been awarded.
- Consent is no longer required from Worldwide Cancer Research before commercialisation of Intellectual Property but the Charity must be notified in a timely manner of any patents or licensing agreements relating to the funded research.
- IP revenue expectations of the Charity have been reviewed and simplified to align better with international expectations with a flat rate of 10% of Net Revenue from commercialisation rather than the previous expectation of 50% share of Net Revenue negotiated dependent on other financial contributions.
- Liability clauses have been updated to reflect current requirements.

The new Terms and Conditions came into effect in 2025.

This is the schedule referred to in the foregoing Award Agreement between Worldwide Cancer Research and «Grant Host Institution Legal Name»

Schedule - Part 1

Terms and Conditions for Research Grant Award

1. Offer of Research Grant Award and Basis of Contract

- 1.1. Worldwide Cancer Research shall make the Grant available to the Host Institution in accordance with the Award Agreement.
- 1.2. No variation of the Award Agreement shall be effective unless such variation is in writing and signed by an authorised signatory of Worldwide Cancer Research.
- 1.3. Worldwide Cancer Research reserves the right to amend these Terms and Conditions or applicable policies at any time. The Host Institution will be informed of any amendments.
- 1.4. In the event of a conflict between the Terms and Conditions and the Award Letter, the Award Letter shall prevail.
- 1.5. Should the Host Institution choose to accept the offer of the Grant as set out in the Award Agreement, the Host Institution shall complete the acceptance process set out in the Award Letter. If the Host Institution is unable to complete the acceptance process or accept these Terms and Conditions, Worldwide Cancer Research may withdraw the offer contained in the Award Agreement without incurring any liability to the Host Institution.
- 1.6. The Host Institution shall:
 - 1.6.1. comply with the Award Agreement and all applicable policies detailed on the Website;
 - 1.6.2. ensure that the Principal Investigator and all individuals and institutions involved in the Project are aware of and comply with the terms of the Award Agreement and all applicable policies;
 - 1.6.3. support the Principal Investigator to deliver the Project as outlined in the Application;
 - 1.6.4. obtain written approval from Worldwide Cancer Research in respect of any requested change to the Start Date (which, in all cases, shall be no later than 6 months from the Start Date set out in the Award Letter).
 - 1.6.5. provide information to Worldwide Cancer Research on any staff or individual working on the Project as soon as such information is available;
 - 1.6.6. obtain, and provide written confirmation upon request to Worldwide Cancer Research of, all ethical approvals, consents and licences required to deliver the Project.
 - 1.6.7. promptly supply any information, documentation, and materials in respect of the Project and/or Award Agreement that is requested by Worldwide Cancer Research to support the administration of the award; and
 - 1.6.8. be responsible and liable for the actions and omissions of its employees, sub-contractors, collaborating institutions, and agents in connection with the Project and the Award Agreement.

2. Definitions and Interpretation

- 2.1. Words and expressions in these Terms and Conditions shall have the same meanings as attributed to them in the Award Letter. Otherwise, the definitions and rules in this clause 2 apply to these Terms and Conditions:

Annual Budget:	the budget produced by Worldwide Cancer Research annually to be deducted from the Grant amount set out in the Award Letter.
Annual Reconciliation Period:	the period of one (1) calendar year commencing on the Start Date (or, for each subsequent Grant Year, the annual anniversary of the Start Date).
Application:	the grant application in respect of the Project submitted to Worldwide Cancer Research by the Host Institution.
Award Agreement:	the Award Letter (including any annexes thereto), and its Schedule, including these Terms and Conditions.
Award Letter:	the letter from Worldwide Cancer Research offering the Grant to the Host Institution, to which this Schedule is attached.
Costs:	all external expenses incurred and paid by the Host Institution in connection with the filing, prosecution and maintenance of Intellectual Property rights in the Results including, but not limited to, official filing fees, agent costs, and reasonable legal and other advisory and consultancy fees. For the avoidance of doubt: (i) Costs shall not include internal costs of the Host Institution relating to these activities, regardless of the legal constitution of Host Institution's TTO; and (ii) any chargeable TTO translation costs shall not exceed

10% of Gross Revenue following the deduction of direct costs, and where the Host Institution wishes to seek costs higher than such 10%, the granting of such shall be at the discretion of Worldwide Cancer Research, subject to the Host Institution demonstrating why higher translation costs are required. For the avoidance of doubt, Costs shall not include salary or taxes in respect of Host Institution's or its TTO personnel or the inventors or generators of the Results.

Data Protection Laws:	all applicable data protection and privacy legislation in force from time to time in the UK including the UK GDPR; the Data Protection Act 2018 (DPA 2018) (and regulations made thereunder); and the Privacy and Electronic Communications Regulations 2003 (SI 2003 No. 2426) as amended; and all other legislation and regulatory requirements in force from time to time which apply to a party relating to the use of Personal Data (including the privacy of electronic communications); and the guidance and codes of practice issued by the Information Commissioner or other relevant data protection or supervisory authority and applicable to a party.
Departure Date:	the date stipulated in a novation agreement upon which the Award Agreement will transfer to the relevant Successor Institution.
End Date:	the date on which the Project is completed.
Equipment:	any and all equipment purchased wholly or partially with the Grant.
Final Reconciliation Period:	the period from the date of the last provided interim reconciliation until the End Date.
Grant:	the sums payable to the Host Institution in respect of the Project as set out in the Award Letter.
Grant Year:	until the End Date, each 12 month period commencing on the Start Date (or any subsequent anniversary thereof) (or any pro-rata portion thereof in respect of periods of less than 12 months).
Gross Revenue:	consideration received by the Host Institution from any commercial exploitation of the Results and/or the Intellectual Property in the Results), including (but not limited to) licence fees, option fees, up-front fees, royalties, minimum royalties and milestone payments, sub-licence initiation fees and any other monetary or in-kind compensation received by the Host Institution from the licensing or other exploitation or disposal of the Results and/or the Intellectual Property in the Results) in forms including but not limited to monies, shares, or options and any other form of non-cash income. It is intended to cover all cash and non-cash income that the Host Institution receives.
Intellectual Property:	all patents, rights to inventions, utility models, materials, copyright and related rights, trademarks, service marks, trade, business and domain names, rights in trade dress or get-up, rights in goodwill or to sue for passing off, unfair competition rights, rights in designs, rights in computer software, database right, topography rights, moral rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications for and renewals or extensions of such rights, and all similar or equivalent rights or forms of protection in any part of the world which derive from the Project.
Net Revenue:	Gross Revenue minus Costs.
Open Access Publishing Policy:	Worldwide Cancer Research's policy on publishing and open access as available on the Website, as updated from time to time.
Parties:	the parties to this Agreement, being Worldwide Cancer Research and the Host Institution.
Payment Schedule:	the schedule for payments of the Grant, detailed at Part 3 of the Schedule.
Personal Data:	as defined in the Data Protection Laws.
Principal Investigator:	the individual identified as the lead applicant in the Application.
Progress Report:	a scientific report on the progress made towards achieving the objectives set out in the Application.
Project:	the project set out in the Award Letter, as further detailed in the Application.
Research Grant Award:	the award of the Grant to the Host Institution in accordance with the Award Agreement.
Results:	any information, data, material, inventions or other results that arise during the performance of the Project.

Start Date:	the commencement date of the Grant as stipulated in the Award Letter.
Successor Institution:	any university, research organisation or other institution to whom the Host Institution transfers the Grant award as a result of the Principal Investigator changing employment.
Term:	the period between the Start Date and the End Date, or if earlier the date of earlier termination of the Award Agreement.
Terms and Conditions:	the Terms and Conditions contained in this Schedule to the Award Letter.
TO:	the technology transfer office of an institution (or equivalent body, howsoever constituted, even if legally separate from the institution) that manages the protection and exploitation of the institution's Intellectual Property.
UK GDPR:	has the meaning given to it in section 3(10) (as supplemented by section 205(4)) of the Data Protection Act 2018.
Website:	Worldwide Cancer Research's website, found at https://www.worldwidecancerresearch.org/ or at such other domain as notified by Worldwide Cancer Research from time to time.

- 2.2. Clause and paragraph headings shall not affect the interpretation of the Award Agreement.
- 2.3. A person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality) and that person's legal and personal representatives, successors and permitted assignees.
- 2.4. Words in the singular shall include the plural and vice versa.
- 2.5. A reference to a statute, statutory provision, or any subordinate legislation made under a statute is to such statute, provision or subordinate legislation as amended or re-enacted from time to time and, in the case of a statute, includes any subordinate legislation made under that statute.
- 2.6. A reference to writing or written includes email.
- 2.7. Any phrase introduced by the terms including, include, in particular or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms.

3. Provision of Grant

- 3.1. Worldwide Cancer Research shall make available the Grant to the Host Institution as set out in the Award Agreement solely for the purpose of enabling the Host Institution to carry out the Project. Such provision of the Grant is subject to: (i) the availability of funds; and (ii) the Host Institution's compliance with the Award Agreement.
- 3.2. The Host Institution shall complete the Project: (i) by the End Date, or any date agreed in writing between the Parties; and (ii) at a cost not exceeding the value of the Grant. The Host Institution acknowledges that Worldwide Cancer Research shall not provide any funding in excess of the value of the Grant.
- 3.3. The Host Institution shall make no changes to the Project without the prior written approval of Worldwide Cancer Research.

4. Annual Budget and Payment of Grant

- 4.1. The Grant amount set out in the Award Letter shall be split into annual amounts by Worldwide Cancer Research via the Annual Budget. The Annual Budget and Payment Schedule shall be solely determined by Worldwide Cancer Research based on information received through the Application and amended subject to clause 5.7.
- 4.2. The Annual Budget shall not increase in line with inflation or any other form of pay adjustment, and Worldwide Cancer Research shall not fund or reimburse any increased pay awards, bonuses, merit awards or other changes to employee salaries.
- 4.3. Each Grant Year shall have its own Annual Budget and no funding shall be carried from one Annual Budget into another Grant Year's Annual Budget without the prior written consent of Worldwide Cancer Research (such consent being at Worldwide Cancer Research's sole discretion and subject to the provision of sufficient scientific justification). Any sums remaining in an Annual Budget, after the reconciliation process at clause 5, shall be retained by Worldwide Cancer Research and shall no longer be made available to the Host Institution.
- 4.4. The transfer of allocated funds between the budget headings detailed in the Application is only permitted with the prior written consent of Worldwide Cancer Research, such consent being at Worldwide Cancer Research's sole discretion and subject to the provision of sufficient scientific justification.
- 4.5. Subject to clause 5, Worldwide Cancer Research shall pay the Annual Budget to the Host Institution, quarterly in arrears, in accordance with the Payment Schedule.
- 4.6. Payments will be remitted in GBP (£ Sterling) and converted to the currency of request by the bank at its exchange rate on the day of the transfer. Worldwide Cancer Research is not responsible for losses incurred through fluctuations in exchange rates and cannot be claimed against the Grant.
- 4.7. The final payment of the Grant, as detailed in the Payment Schedule, will only be paid following:

- 4.7.1. submission of the final reconciliation in accordance with clause 5;
- 4.7.2. submission of the final Progress Report as set out in clause 6; and
- 4.7.3. acceptance of the final reconciliation and final scientific report by Worldwide Cancer Research.

4.8. Following the final payment of the Grant detailed in the Payment Schedule, Worldwide Cancer Research shall not accept or reimburse any further claims or requests for payment.

4.9. The Host Institution is not entitled to any additional charges such as overheads, bench fees, publication or administrative costs. The Host Institution may only be reimbursed for costs incurred which are within the remit of the Grant. The Host Institution undertakes to meet all other costs, taxes, charges and liabilities not covered by the Grant but necessary for the Host Institution to successfully carry out the Project.

5. Reconciliations

- 5.1. The Host Institution shall provide to Worldwide Cancer Research an interim reconciliation on an annual basis, no later than three (3) months following the end of the relevant Annual Reconciliation Period.
- 5.2. If: (i) the interim reconciliation is not received within the time specified at clause 5.1; or (ii) Worldwide Cancer Research does not consider the information provided by the Host Institution to be complete and adequate, Worldwide Cancer Research reserves the right to suspend payments of the Award until such time as the Host Institution provides complete and adequate information.
- 5.3. The Host Institution shall submit a final reconciliation to Worldwide Cancer Research within three (3) months of the End Date.
- 5.4. As part of each interim reconciliation and final reconciliation, the Host Institution shall:
 - 5.4.1. set out all eligible costs based on actual expenditure incurred by the Host Institution in carrying out the Project during the Annual Reconciliation Period or Final Reconciliation Period; and
 - 5.4.2. provide accompanying invoices and documentation for any costs detailed in the Annual Reconciliation Period or Final Reconciliation Period.
- 5.5. All reconciliations submitted to Worldwide Cancer Research and all accompanying documentation must be provided in English (or an English translation provided).
- 5.6. All figures should be entered in GBP (£ Sterling) on the reconciliation form.
- 5.7. Any overspend or underspend revealed during the reconciliation process under any budget heading will be deducted from available budget under the relevant heading in the following year (or, if such overspend or underspend occurs in the final Grant Year, Worldwide Cancer Research shall invoice the Host Institution for any such amount following the final reconciliation and the Host Institution shall pay each invoice within thirty (30) days of the date of the invoice).
- 5.8. It is the Host Institution's responsibility to ensure that any requested reports and reconciliations are submitted within the timescales stated herein. Acceptance of such is at the discretion of Worldwide Cancer Research. The Host Institution's failure to adhere to this Clause 5 shall be deemed a material breach.
- 5.9. The Host Institution shall be responsible for repaying to Worldwide Cancer Research immediately upon receipt of a written demand by Worldwide Cancer Research any Grant funds which have been remitted to the Institution in the absence of adequate supporting documentation. Payment of Grant funds shall be made in accordance with the conditions of payment detailed in the Award Agreement.
- 5.10. If the Principal Investigator ceases to be employed by the Host Institution, Worldwide Cancer Research shall determine whether the Grant: (i) shall be transferred to a suitable candidate with the Host Institution; (ii) shall be transferred to a succeeding Host Institution (Clause 15); or (iii) shall be terminated (Clause 14).
- 5.11. If the Principal Investigator ceases to be employed or otherwise engaged by the Host Institution for any reason, the Host Institution shall inform Worldwide Cancer Research at least one (1) calendar month in advance of the date of the Principal Investigator's employment with the Host Institution ending.
- 5.12. Upon being notified that the Principal Investigator's employment with the Host Institution is ending or is due to end:
 - 5.12.1. Worldwide Cancer Research shall be entitled to withhold future payment of the Grant pending submission of a satisfactory reconciliation form (in accordance with the standards set out in this clause 5 by the Host Institution);
 - 5.12.2. in the event that the Principal Investigator and Host Institution wish for the Grant to transfer to the Principal Investigator's new employer, the Principal Investigator shall submit a request to Worldwide Cancer Research with a case for the suitability of the intended Successor Institution to take over the Grant, alongside notification of their employment ending with the Host Institution in accordance with clause 5.11;
 - 5.12.3. the Host Institution shall submit a final reconciliation form within 3 months of the Principal Investigator's employment with the Host Institution ending;
 - 5.12.4. such a reconciliation shall be used by Worldwide Cancer Research to determine any final payment of Grant which may be due to the Host Institution prior to any decision under clause 5.10 over the future of the Grant; and

5.12.5. in the event of overpayment within the Grant Year, Worldwide Cancer Research shall invoice the Host Institution for the outstanding amount and the Host Institution shall pay the amount identified in any such invoice within thirty (30) days of the date on the invoice.

6. Progress Reports

6.1. Payment of the Grant is conditional upon the Host Institution submitting satisfactory Progress Reports according to the table set out in this clause 6.1 that Worldwide Cancer Research has accepted and approved in accordance with clause 6.2.

Period of Project to be Covered by Report	Report Due to be Submitted to Worldwide Cancer Research
month 1 - month 6	prior to grant payment at month 9
month 7 - month 18	prior to grant payment at month 21
month 18 – End Date	prior to final grant payment within 3 months after End Date

6.2. Acceptance and approval of any Progress Report submitted in accordance with clause 6.1 shall be at the sole discretion of Worldwide Cancer Research.

6.3. In accordance with clause 4.7, the final payment of the Grant shall be withheld by Worldwide Cancer Research pending completion of the final report detailed at clause 6.1.

6.4. In addition to the Progress Report requirements at clause 6.1, the Host Institution shall also submit short follow up reports on the third and sixth anniversaries of the End Date when requested.

7. Management of Research Grant Award

7.1. Worldwide Cancer Research shall only make payment of the Grant to the Host Institution and shall not in any circumstances be responsible for reimbursing or making payment to any third party institution, person or organisation involved in the Project.

7.2. Where the Application indicates that another organisation is involved in the Project, it shall be the responsibility of the Host Institution to allocate funds to any such organisation and to ensure that any such collaborating party or third-party organisation: (i) is reimbursed in accordance with the Annual Budget; and (ii) complies with the terms and conditions of this Award Agreement.

7.3. Where any part of the Project will be carried out by a third party, the Host Institution shall ensure that such third party is bound by a written collaboration agreement or subcontract, as appropriate. The Host Institution shall ensure that such written agreement flows down the terms of this Award Agreement, including (without limitation) vesting all Results and Intellectual Property in the Results in the Host Institution on creation. The Host Institution shall provide Worldwide Cancer Research with a copy of any such agreement on request.

7.4. The Host Institution shall be responsible and liable for proper financial management of the Grant and use of charitable funds, including the creation and retention of records of expenditure in connection with the Grant. The Host Institution shall provide such records to Worldwide Cancer Research upon request. The Host Institution must keep in place all procedures and security arrangements which enable it to monitor and protect against fraudulent activity, bribery, and any other illegal practices.

7.5. The Host Institution shall comply (and shall ensure that any collaborating organisations and subcontractors comply) with Worldwide Cancer Research's rules, policies and procedures. Worldwide Cancer Research's research policies can be found on the Website and concern animal research, human stem cell research, tobacco industry funding, open access publishing, conflict of interest and research funding.

7.6. The Host Institution shall not accept any other grant or research funding to carry out the Project, or any part of it, without the prior approval of Worldwide Cancer Research.

8. Staff and Equipment

8.1. The Principal Investigator may work on the Project independently or opt to work on the Project in partnership with or with assistance from research workers (each of whom may or may not be receiving support from Worldwide Cancer Research in their own right). The costs incurred by the Host Institution as a result of the employment or engagement of the Principal Investigator and any research workers or staff members who are involved with the Project shall be the responsibility of the Host Institution. Worldwide Cancer Research shall only reimburse eligible staff related costs where they have been appropriately detailed in the Application and approved through the Annual Budget.

8.2. Nothing in the Award Agreement shall render the Principal Investigator nor any research worker or staff member who is involved with the Project an employee, worker, agent or partner of Worldwide Cancer Research. The Host Institution shall ensure that any research worker or staff member who is involved with the Project, including the Principal Investigator, shall not hold him/herself out as an employee, worker, agent or partner of Worldwide Cancer Research.

8.3. The relationship of the Host Institution (and the Principal Investigator or any other staff working on the Project) to Worldwide Cancer Research will be that of independent contractor and nothing in this Agreement shall render it (nor the Principal Investigator or any other staff working on the Project) an employee, worker, agent or partner of Worldwide Cancer Research and the Host Institution shall not hold itself out as such and shall procure that the Principal Investigator or any other staff working on the Project shall not hold themselves out as such.

8.4. Worldwide Cancer Research shall not be entitled to and will not seek to exercise any supervision, direction or control over the Host Institution or the Principal Investigator (or any substitute) in the manner of performance of the Project, save that Worldwide Cancer Research shall give reasonable and lawful instructions as may be needed to direct the Host Institution as to how the Project should be carried out.

8.5. The Host Institution shall be fully responsible for and shall indemnify Worldwide Cancer Research for and in respect of the following:

- 8.5.1. any income tax, National Insurance and social security contributions (and any equivalent in any other jurisdiction) and any other liability, deduction, contribution, assessment or claim: (i) arising from a determination that the Project and/or Grant is deemed employment; or (ii) made in connection with either the performance of the Project or any payment or benefit received by the Principal Investigator (or any other individual working on the Project) in respect of the Project, where such recovery is not prohibited by law. The Host Institution shall further indemnify Worldwide Cancer Research against all reasonable costs, expenses and any penalty, fine or interest incurred or payable by Worldwide Cancer Research in connection with or in consequence of any such liability, deduction, contribution, assessment or claim;
- 8.5.2. any liability arising from any employment-related claim or any claim based on worker status (including reasonable costs and expenses) brought by the Principal Investigator, any substitute or any other individual working on the Project against Worldwide Cancer Research arising out of or in connection with the provision of the Grant and/or Project, except where such claim is as a result of any act or omission of Worldwide Cancer Research.

8.6. The Grant may only be used to cover the cost of the salary of replacement staff members to take the place of staff members who are absent due to period of maternity, paternity or sickness absence with the prior written consent of Worldwide Cancer Research. The Grant may not be used to meet the cost of sick leave or maternity, paternity or adoption leave for staff who are paid salaries from the Grant. As set out at clause 8.1, the costs incurred by the Host Institution as a result of the employment or engagement of the Principal Investigator and any research workers or staff members who are involved with the Project shall be the responsibility of the Host Institution and it is the Host Institution's responsibility to ensure that it complies with its obligations under employment law in respect of them.

8.7. Upon receipt of a written request from Worldwide Cancer Research, the Host Institution shall provide Worldwide Cancer Research with the attendance records of any staff member who is funded by the Grant. If such records show that Worldwide Cancer Research has unknowingly or mistakenly reimbursed the Host Institution for the cost of paid maternity, paternity, adoption or sick leave for any member of staff paid a salary from the Grant, the Host Institution shall repay the full amount of such payment to Worldwide Cancer Research.

8.8. The Host Institution shall ensure that all advertisements for staff to be appointed or employed in relation to the Project clearly state that the Project is funded by Worldwide Cancer Research.

8.9. The Host Institution undertakes to disclose to Worldwide Cancer Research the details of, and any alteration to, each individual appointed to work on the Project as soon as is practicable after the appointment.

8.10. Notwithstanding anything in this clause 8, staff expenses payable under the Grant shall in all circumstances be limited to the amount which is detailed in the Annual Budget.

8.11. Subject to Clause 15.2, all Equipment shall be the property and responsibility of the Host Institution.

8.12. The Host Institution shall maintain the Equipment at its own expense in good and substantial repair in order to keep it in good operating condition including replacement of worn, damaged and lost parts, and shall make good any damage to the Equipment. Worldwide Cancer Research shall not reimburse the cost of replacement Equipment and shall not reimburse the cost of repairs to damaged Equipment.

8.13. The Host Institution shall not without the prior written consent of Worldwide Cancer Research part with control of (including for the purposes of repair or maintenance), sell or offer for sale, underlet or lend the Equipment or allow the creation of any mortgage, charge, lien or other security interest in respect of it.

9. Media and Publications

9.1. Subject to this clause 9 and clause 10, the Host Institution undertakes to disseminate Results, always in accordance with the Open Access Publishing Policy.

9.2. The Host Institution shall not (and shall ensure that no one working on the Project shall) enter into any restrictive publication arrangements in relation to any Results connected with or arising from the Project, including any arrangements which may conflict with the Open Access Publishing Policy.

9.3. The Host Institution shall:

- 9.3.1. provide Worldwide Cancer Research (by email to grants@worldwidelcancerresearch.org) with an advance copy of all publications arising from the Grant and/or Project no later than thirty (30) working days in advance of submission for publication;
- 9.3.2. notify Worldwide Cancer Research at the time of providing an advance copy under clause 9.3.1 if any information, data, Results or Intellectual Property contained in the publication is capable of Intellectual Property protection;
- 9.3.3. inform and co-ordinate with Worldwide Cancer Research for any press releases on the Project funding and results.
- 9.3.4. provide Worldwide Cancer Research with photographs and support the creation and delivery of other resources as reasonably requested for use on websites, fundraising, publicity and other materials; and
- 9.3.5. acknowledge the financial assistance given by Worldwide Cancer Research in all press or media releases and all publications, published documents or presentations related to the Grant. Worldwide Cancer Research should be acknowledged in all such publications, documents and presentations using the format: "This work was supported by Worldwide Cancer Research (grant reference number xx-xxxx)".

- 9.4. If anything contained in a publication submitted to Worldwide Cancer Research under clause 9.3 is capable of Intellectual Property protection, the Host Institution shall not publish (and shall ensure that no others involved in the Project publishes) such publication until such time as: (i) it has consulted with Worldwide Cancer Research in accordance with clause 9.3.2; and (ii) in consultation with Worldwide Cancer Research, the appropriate intellectual property protection has been sought and approved. If Worldwide Cancer Research or its agent ask for a publication to be delayed to protect intellectual property potential, an agreed approach must be decided within three (3) months of receiving notification to publish.
- 9.5. Worldwide Cancer Research may use the Application (including details of staff named in the Application, their qualifications and employment history), Progress Reports, final interim and follow up reports in such manner as it sees fit and may copy, publish and distribute the applications and such reports or parts of them in any part of the world without payment to the Host Institution or any other person or organisation working on the Project provided that: (i) such use respects the confidential nature of any such material contained within these documents; (ii) that in doing so it acknowledges the source of the material; and (iii) Worldwide Cancer Research complies with all Data Protection Laws.
- 9.6. Worldwide Cancer Research reserves the right to publish details of the Grant, including the name of the Principal Investigator, the name of the Host Institution, the title of the Project, the Research Grant Award, biographical materials (including high resolution photographs of the Principal Investigator, and other lab members), and a summary of the Project on the Worldwide Cancer Research website, the International Cancer Research Partnership website and in relevant publications.
- 9.7. The Host Institution shall ensure that the Principal Investigator shall, upon request, act as an external referee for Worldwide Cancer Research to help it assess other grant applications.
- 9.8. The Host Institution shall include Worldwide Cancer Research's logo (as provided by Worldwide Cancer Research from time to time) on all presentation slides and/or paperwork, posters, handouts and laboratory websites relating to the Project. Worldwide Cancer Research hereby grants to the Host Institution a non-exclusive, non-transferable, non-sublicensable, royalty-free licence for the Term to the Worldwide Cancer Research logo to the extent necessary to comply with this clause 9.8.
- 9.9. This clause 9 shall continue in full force and effect indefinitely during the Term and following the expiration or termination of this Award Agreement.

10. Intellectual Property & IP Revenue Sharing

- 10.1. The Results (and any Intellectual Property therein) shall be owned by the Host Institution.
- 10.2. In addition to its obligations under clause 9.3.2, the Host Institution shall, on a continuing basis throughout the Term, inform Worldwide Cancer Research of all Results (including any Intellectual Property rights they may contain) which might be suitable for Intellectual Property protection and/or commercial exploitation. The Host Institution shall not publish (or make available in any other form of public presentation) any Results unless authorised in accordance with clause 9.4.
- 10.3. Subject to clause 9 and this clause 10, the Host Institution shall identify and implement strategies for the identification, protection and exploitation of all Results and the Intellectual Property in the Results funded by the Grant.
- 10.4. Subject to clause 9 and this clause 10, the Host Institution shall use all reasonable endeavours to commercialise the Results, except where otherwise agreed with Worldwide Cancer Research. Host Institution shall not enter into any arrangements, including any commercial or non-commercial licence or assignation, which would limit or exclude or which has the potential to limit or exclude the use of Results (including any Intellectual Property Rights they may contain) for the benefit of further cancer research, clinical trials or for authorised use in cancer patients. If Worldwide Cancer Research, acting reasonably, in its sole discretion considers that the Host Institution has entered into any arrangement in breach of this clause 10.3, Worldwide Cancer Research may require the Host Institution to immediately terminate such arrangement, and the Host Institution shall ensure that any arrangement it enters into in respect of the Results shall include a provision allowing such termination.
- 10.5. The Host Institution shall, at its own cost and expense, obtain and maintain protection of any and all Intellectual Property in the Results which is capable of being protected.
- 10.6. Worldwide Cancer Research reserves the right to exploit (either itself or through its agent) the Results and/or apply for patents and other registrable Intellectual Property in its own name relating to the Results, if and to the extent that:
 - 10.6.1. the Host Institution does not take active steps to protect or exploit the Results and/or Intellectual Property in the Results, to the extent that such Results and/or Intellectual Property in the Results, are capable of protection and/or exploitation (in such circumstances, the Host Institution shall provide justification to Worldwide Cancer Research on why such steps have not been taken);
 - 10.6.2. the Host Institution notifies Worldwide Cancer Research that it does not intend to protect or exploit the Results where such Results and/or Intellectual Property in the Results, are capable of the same; or
 - 10.6.3. the Parties agree that Worldwide Cancer Research (or its agent) will take forward any such protection or exploitation.
- 10.7. The Host Institution shall co-operate fully with Worldwide Cancer Research (or its agent) in entering into such other documents and taking such steps at the expense of Worldwide Cancer Research (or its agent) as may be reasonably necessary to allow Worldwide Cancer Research (or its agent) to exercise its rights under clause 10.6.
- 10.8. In the event a patent application for protection of Intellectual Property connected to the Results has been filed, the Host Institution shall notify Worldwide Cancer Research and provide information on the data covered by the patent and all relevant filing information to Worldwide Cancer Research no later than three (3) months after filing.

10.9. The Host Institution shall, within thirty (30) days of any agreement, including a licensing agreement, relating to any of the Results and/or the Intellectual Property in the Results being signed, notify Worldwide Cancer Research of such fact and the Host Institution shall provide, on a confidential basis, to Worldwide Cancer Research a copy of any such agreement if requested.

10.10. In the event that the Host Institution commercialises any Results and/or Intellectual Property in the Results (whether by licensing, disposing of, or otherwise exploiting such Results) and/or Intellectual Property, the Host Institution shall (within three (3) months of such commercialisation) enter into a revenue sharing agreement (the "RSA") with Worldwide Cancer Research. The RSA will be on fair and reasonable terms to be agreed between the Parties, and will provide for the payment of a 10% share of the Net Revenue to Worldwide Cancer Research.

10.11. Within thirty (30) days of each annual anniversary of the Start Date, or such other time as agreed in the RSA, the Host Institution shall pay to Worldwide Cancer Research 10% of all Net Revenue generated during the calendar year immediately preceding such anniversary.

10.12. All payments to Worldwide Cancer Research shall be made in pounds (£) sterling.

10.13. The Host Institution shall, on the anniversary of the date agreed between the parties (or the Start Date if no date is agreed), provide Worldwide Cancer Research with a statement of all Gross Revenue received and Costs incurred in connection with the protection of the Results during the calendar year immediately preceding such Date.

10.14. The Host Institution shall be responsible for maintaining records of all Gross Revenue, Equity, Net Revenue, Costs, taxes, exploitation and commercialisation activities relating to the Results and Intellectual Property in the Results and shall provide access to, or copies of, such records upon reasonable written request by Worldwide Cancer Research (or its Agent).

11. Scientific Integrity

11.1. The Host Institution shall be responsible for investigating any allegation or suspicion of scientific fraud, research misconduct or any other issues affecting the delivery or management of the Project.

11.2. The Host Institution shall have appropriate policies in place to support scientific best practice and delivery of the Project, including policies on scientific fraud and research misconduct.

11.3. If an issue of scientific fraud, research misconduct, or an ethical issue is suspected or alleged in connection with the Project, the Host Institution shall:

11.3.1. notify Worldwide Cancer Research as soon as it is aware of the alleged or suspected issue; and

11.3.2. update Worldwide Cancer Research on any further developments regarding any investigation taking place into the issue and provide such information as is necessary to allow for effective management of the Grant and monitoring of such by Worldwide Cancer Research.

11.4. If, in Worldwide Cancer Research's reasonable opinion, the Host Institution has failed to take appropriate steps to investigate any suspicion or accusation regarding scientific fraud or research misconduct, Worldwide Cancer Research shall be entitled to suspend the Grant until such time as it is satisfied that the Host Institution has taken appropriate steps.

11.5. Where an investigation results in a case of scientific fraud and/or research misconduct being proven, Worldwide Cancer Research reserves the right to terminate the Grant immediately and to require the Host Institution to repay any payments made under the Grant to Worldwide Cancer Research.

11.6. The Host Institution shall meet with Worldwide Cancer Research (or its agent) upon the reasonable request of Worldwide Cancer Research and provide such information or updates relating to the Project (including in relation to the Results) as is reasonably requested by Worldwide Cancer Research.

12. Research Governance

12.1. The Host Institution must ensure that all research, experiments and activities undertaken in relation to the Project conform with all relevant laws and regulations which apply to such activities.

12.2. The Host Institution undertakes to ensure that, at all times during the Term:

12.2.1. all research is conducted to the appropriate ethical standards;

12.2.2. all research is conducted to the appropriate scientific standards;

12.2.3. all information relating to the Project is handled, stored, and disseminated properly;

12.2.4. all appropriate health and safety regulations are enforced and followed;

12.2.5. proper financial and accounting procedures are followed; and

12.2.6. a quality research culture is fostered within the Host Institution.

12.3. The Host Institution and any third parties working on the Project are required to comply with Worldwide Cancer Research's rules, policies and procedures (including but not limited to those on use of animals in research, human stem

cell research, tobacco industry funding, open access publishing, conflict of interest and research funding privacy), as updated on the Website from time to time. Additional information not available on the Website may be communicated to the Host Institution by Worldwide Cancer Research from time to time.

13. Liability

- 13.1. Nothing in this Award Agreement shall limit or exclude either Party's liability in respect of: (i) death or personal injury resulting from that Party's negligence; (ii) fraud or fraudulent misrepresentation; or (iii) any other sort of liability which may not legally be so limited or excluded.
- 13.2. The sole financial obligation of Worldwide Cancer Research under or in connection with the Award Agreement shall be its obligation to pay the Grant in accordance with the Award Agreement.
- 13.3. Subject to clauses 13.1 and 13.2, Worldwide Cancer Research excludes all its liability (howsoever arising, including through negligence) to the Host Institution.
- 13.4. The Host Institution hereby holds harmless and indemnifies Worldwide Cancer Research against any and all losses, damages, expenses or costs which Worldwide Cancer Research suffers or incurs (including in respect of any third party claims) in connection with: (i) the Award Agreement; (ii) the Project; or (iii) the Results, in each case which arise as a result of, or in connection with, the actions or omission of the Host Institution or any party working on the Project.

14. Termination

- 14.1. Worldwide Cancer Research shall be entitled to suspend, terminate or reclaim the Grant in whole or in part including but not limited to where:
 - 14.1.1. the Host Institution fails to submit any reports, records or reconciliations required under this Award Agreement on time or to the standard required;
 - 14.1.2. in the reasonable opinion of Worldwide Cancer Research, the Host Institution has failed to maintain progress on the Project; or
 - 14.1.3. the Host Institution has breached or failed to comply with the Award Agreement.
- 14.2. Worldwide Cancer Research may terminate the Award Agreement with immediate effect, with no liability to make any further payment of the Grant (except, at Worldwide Cancer Research's sole discretion, in respect of any properly accrued expenditure at the date of termination) in the event that:
 - 14.2.1. the Host Institution is in material breach of any of its obligations under the Award Agreement;
 - 14.2.2. Worldwide Cancer Research, at its sole discretion, believes scientific or financial misconduct has taken place in connection with the Project;
 - 14.2.3. the Host Institution has entered or is threatening to enter an insolvency event or otherwise suspends or ceases, or threatens to suspend or cease, carrying on all or a substantial part of its business;
 - 14.2.4. there is a material change of circumstances relating to either the Host Institution or the Project which, in the reasonable opinion of Worldwide Cancer Research, fundamentally changes the circumstances on which Grant was awarded;
- 14.3. In the event that the Host Institution wishes to terminate the Award Agreement, it must provide a written statement justifying the reasons for the termination to Worldwide Cancer Research, four (4) weeks prior to the termination coming into effect.
- 14.4. Upon initiating or receiving a notice of termination, the Host Institution shall:
 - 14.4.1. provide a Progress Report covering the period from the last provided Progress Report until the date of termination; and
 - 14.4.2. submit a final reconciliation form (which shall be in accordance with the requirements of clause 5).
- 14.5. Termination of the Award Agreement under terms of this clause 14 is without prejudice to the rights and duties of each Party accrued prior to the date of termination. A concluding letter will be issued by Worldwide Cancer Research upon: (i) satisfactory receipt of the items listed in clause 14.3 and 14.4; and (ii) reimbursement to Worldwide Cancer Research by the Host Institution of any uncommitted funds as determined during the Final Reconciliation.
- 14.6. The following clauses of these Terms and Conditions shall continue to apply after the End Date: 1.2, 1.4, 1.6.7, 1.6.8, 2, 4.3, 4.6, 4.7, 4.8, 4.9, 5.1–5.9(inclusive), 5.12, 6, 7.1, 7.2, 7.4, 7.6, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.11, 8.13, 9, 10, 11.1, 11.3, 13, 14.5, 14.6, 15, 16, 17, 18, 19, 20, 21.

15. Change of Institution

- 15.1. Should the Principal Investigator leave their employment with the Host Institution and Worldwide Cancer Research approves the transfer of the Grant to a Successor Institution in accordance with clause 5.10.
 - 15.1.1. The Host Institution shall complete a final reconciliation in accordance with clause 5.12;
 - 15.1.2. The Host Institution shall enter into a novation agreement between the Host Institution, the Successor Institution and Worldwide Cancer Research;

- 15.1.3. The Host Institution shall co-operate to assist in the transfer of the Grant and shall execute any paperwork required to effect the transfer of the Grant;
- 15.1.4. From the Departure Date, the Host Institution shall cease to be a party to the Award Agreement subject to clause 14.6; and
- 15.1.5. Subject to the written consent of Worldwide Cancer Research and completion of the process set out in this clause 15.1, the Successor Institution shall be free to accept and undertake responsibility for the continuing administration of the Project, on the terms set out in this Award Agreement and/or on any other terms that Worldwide Cancer Research may in its absolute discretion conclude with the Successor Institution.
- 15.2. If the Grant transfers to a Successor Institution, the Equipment shall become the property and responsibility of that Successor Institution. The Host Institution shall enter into such documents as is necessary to effect such transfer.
- 15.3. If Worldwide Cancer Research does not consent to the transfer of the Grant to the Successor Institution, and no suitable alternative can be agreed (in the opinion of Worldwide Cancer Research), Worldwide Cancer Research shall have the right to immediately terminate the Grant and the Award Agreement.

16. Data Protection

- 16.1. Worldwide Cancer Research will process Personal Data of the Principal Investigator and research personnel of the Host Institution when it is necessary for the purposes of the Award Agreement. This may include for legal, personnel, administrative and management purposes. Personal Data will be processed in compliance with the Data Protection Laws.
- 16.2. All Personal Data will be processed in accordance with the Worldwide Cancer Research's Research Funding privacy notice, which is available on the Worldwide Cancer Research website. When necessary for the performance of the Award Agreement, Worldwide Cancer Research may make Personal Data of the Principal Investigator and research personnel available to third parties who provide services or expertise to Worldwide Cancer Research, and to seek additional funding from our international partners, for grant/expense claim payments and to the International Cancer Research Partnership. Some of these third parties may be based outside of the UK and European Economic Area.

17. Confidentiality

- 17.1. Worldwide Cancer Research will use reasonable endeavours to ensure that any confidential information disclosed to it will be held as confidential. Notwithstanding this, Worldwide Cancer Research may require to disclose confidential information to the extent required by any law or regulation or any court of competent jurisdiction.

18. Notices

- 18.1. Notice given under the Award Agreement shall be in writing, sent for the attention of the person, and to the address, given in the Award Agreement (or such other address, or person as the relevant Party may notify in writing to the other Party) and shall be delivered personally, sent by pre-paid, first-class post or recorded delivery.
- 18.2. A notice is deemed to have been received, if delivered personally, at the time of delivery, in the case of pre-paid first class post or recorded delivery, 48 hours from the date of posting and, if deemed receipt under this clause 18 is not within normal business hours (meaning 8.30 am to 4.30 pm Monday to Friday on a day that is a Business Day), at 8.30 am on the first business day following delivery.

19. Miscellaneous

- 19.1. A waiver of any right under the Award Agreement is only effective if it is in writing and it applies only to the party to whom the waiver is addressed and the circumstances for which it is given.
- 19.2. If any provision of the Award Agreement is found by any court or administrative body of competent jurisdiction to be invalid, unenforceable or illegal, the other provisions will remain in force.
- 19.3. If any invalid, unenforceable or illegal provision would be valid, enforceable or legal if some part of it were deleted, that provision will apply with whatever modification is necessary to make it valid, enforceable and legal.
- 19.4. This Award Agreement constitutes the entire agreement between the Parties. The Parties acknowledge and agree that (save in the case of fraud), in entering into the Award Agreement they do not rely on any undertaking, promise, assurance, statement, representation, warranty or understanding (whether in writing or not) of any person (whether Party to the Award Agreement or not) relating to the subject matter of the Award Agreement other than as expressly set out in the Award Agreement.
- 19.5. The Host Institution shall not, without Worldwide Cancer Research's prior written consent, assign, transfer, charge, sub-contract or deal in any other manner with all or any of the Host Institution's rights or obligations under the Award Agreement. Worldwide Cancer Research may at any time assign, transfer, charge, sub-contract or deal in any other manner with all or any of its rights or obligations under the Award Agreement.
- 19.6. Nothing in the Award Agreement is intended to, or shall operate to, create a partnership between the Parties, or to authorise either Party to act as agent for the other, and neither Party shall have authority to act in the name of or on behalf of or otherwise to bind the other in any way, (including the making of any representation or warranty, the assumption of any obligation or liability and the exercise of any right or power).
- 19.7. No third party shall have any rights to enforce this Award Agreement under the Contract (Third Party Rights) (Scotland) Act 2017.

20. Dispute Resolution

- 20.1. In the event of a dispute arising out of or relating to this contract, including any question regarding its existence, validity or termination, the Parties shall first seek settlement of that dispute by mediation in accordance with the London Court of International Arbitration Mediation Rules, which rules are deemed to be incorporated by reference into this clause 20.
- 20.2. If the dispute is not settled by mediation within 120 days of the commencement of the mediation, or such further period as the Parties shall agree in writing, the dispute shall be referred to and finally resolved by arbitration under the London Court of International Arbitration Rules, which rules are deemed to be incorporated by reference into this clause 20.
- 20.3. The language to be used in the mediation and in the arbitration shall be English.
- 20.4. In any arbitration commenced pursuant to this clause 20,
 - 20.4.1. the number of arbitrators shall be one; and
 - 20.4.2. the seat, or legal place, of arbitration shall be Scotland.

20.5 Nothing in this clause 20 shall prevent either Party from resolving disputes in accordance with clause 21 if a Party considers it is necessary to do so in order to: (i) obtain emergency injunctive relief; or (ii) preserve a cause of action that would otherwise be lost.

21. Law and Jurisdiction

Scots law shall be the applicable law of the Award Agreement and, subject to clause 20, the Scottish courts shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with the Award Agreement or its subject matter.